Zelnorm was a brand of tegaserod sold by Novartis from 2002 to 2007, and later by Alfasigma from 2019 to 2022. The drug was first withdrawn from markets and discontinued in 2007 due to the Food and Drug Administration's concerns about it causing possible adverse cardiovascular effects. It would later be brought back in 2019, but was voluntarily discontinued by its new manufacturer in 2022, citing a business decision rather than any concerns regarding the safety or efficacy of the drug.
2002–2007[]
|
BETTER LOGO NEEDED |
Zelnorm was withdrawn and discontinued in 2007 following concerns about dangerous side effects.
2019–2022[]
|
|
SVG NEEDED |
In 2019, the Zelnorm brand was revived by Alfasigma as a treatment for IBS-C in female patients under 65 years old.
In 2022, it was discontinued by its manufacturer, which cited a business decision rather than any concerns regarding the safety or efficacy of the drug.